Bristol-Myers buys rights to Novo Nordisk immune system project

March 24 (Reuters) - Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research programme, which the Danish company is divesting as it focuses further on diabetes care.